Table 1.

Baseline characteristics of the SPRINT participants with CKD

CharacteristicsIntensive Treatment, n=1330Standard Treatment, n=1316Total, n=2646
Age, mean±SD, yr72.0±9.071.9±9.571.9±9.3
Age ≥75 yr, no. (%)584 (43.9)577 (43.8)1161 (43.9)
Women, no. (%)537 (40.4)521 (39.6)1058 (40.0)
Race or ethnicity, no. (%)
 Non-Hispanic black325 (24.4)312 (23.7)637 (24.1)
 Hispanic94 (7.1)96 (7.3)190 (7.2)
 Non-Hispanic white885 (66.5)893 (67.9)1778 (67.2)
 Other26 (2.0)15 (1.1)41 (1.6)
Serum creatinine, mg/dl
 All1.43 (0.39)1.43 (0.38)1.43 (0.39)
 Age ≥75 yr1.41 (0.38)1.39 (0.31)1.40 (0.34)
 Age <75 yr1.46 (0.41)1.47 (0.42)1.46 (0.41)
eGFR, mean (SD), ml/min per 1.73 m2a
 All47.9 (9.5)47.9 (9.5)47.9 (9.5)
 Age ≥75 yr47.4 (9.5)47.3 (9.0)47.4 (9.2)
 Age <75 yr48.2 (9.4)48.3 (9.9)48.2 (9.7)
Urinary ACR
 Mean (SD), mg/gb80.9 (236.2)80.3 (250.5)80.6 (243.4)
 Median (interquartile range)12.8 (6.5–42.6)13.8 (6.1–43.5)13.3 (6.4–43.1)
BP, mean±SD, mm Hg
 SBP139.1±16.1139.2±16.0139.2±16.1
 DBP75.1±12.274.8±12.274.9±12.2
Distribution of SBP, mm Hg
 ≤132463 (34.8)468 (35.6)931 (35.2)
 >132 to <145425 (32.0)412 (31.3)837 (31.6)
 ≥145442 (33.2)436 (33.1)878 (33.2)
Antihypertensive medications, no. per participant ±SD2.09±1.012.11±1.012.10±1.01
Participants not using antihypertensive medications, no. (%)61 (4.6)62 (4.7)123 (4.7)
Statin use, no. (%)657 (49.7)697 (53.4)1354 (51.5)
Aspirin use, no. (%)754 (56.7)728 (55.5)1482 (56.1)
Smoking status
 Never smoker, no. (%)606 (45.6)601 (45.7)1207 (45.6)
 Former smoker, no. (%)617 (46.4)600 (45.6)1217 (46.0)
 Current smoker, no. (%)107 (8.1)114 (8.7)221 (8.4)
 Missing data, no.011
CVD
 Clinical, no. (%)263 (19.8)257 (19.5)520 (19.7)
 Subclinical, no. (%)121 (9.1)121 (9.2)242 (9.2)
 Framingham score, mean±SD, %27.1±14.327.2±24.327.1±14.3
 Framingham score ≥15%, no. (%)1042 (78.4)1027 (78.2)2069 (78.3)
Body mass index, mean±SDc29.5±5.829.4±5.729.4±5.8
Fasting plasma total cholesterol, mean±SD, mg/dl186.6±40.7184.9±40.6185.8±40.7
Fasting plasma LDL cholesterol, mean±SD, mg/dl108.9±35.0106.0±33.5107.4±34.3
Fasting plasma total triglycerides, mean±SD, mg/dl124.9±69.4133.6±89.0129.2±79.9
Fasting plasma glucose, mean±SD, mg/dl98.2±13.998.3±12.498.2±13.1
  • To convert LDL and total cholesterol to millimoles per liter, multiply by 0.0259. To convert triglycerides to millimoles per liter, multiply by 0.0113, and to convert glucose to millimoles per liter, multiply by 0.0555.

  • a On the basis of the four-variable MDRD equation.

  • b For urinary ACR: n=1284 in the intensive treatment group and n=1270 in the standard treatment group.

  • c Calculated as weight in kilograms divided by height in meters squared.